A method and device for determining antiviral drugs

By using adsorption films prepared by agarose film and specific resin particles in the DGT device, combined with the high-performance liquid chromatography-secondary mass spectrometry combination method, the problem of long-term detection of antiviral drugs in water is solved, and the confrontation is achieved The time average concentration of viral drugs is determined, which improves detection efficiency and accuracy.

CN116251571BActive Publication Date: 2024-11-19NANJING UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202310318321.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-29
Publication Date
2024-11-19
Estimated Expiration
2043-03-29

AI Technical Summary

Technical Problem

The prior art has problems such as long time-consuming, complex operation and only instantaneous concentrations when detecting antiviral drugs in water bodies, making it difficult to accurately reflect the true contamination status of pollutants.

Method used

The DGT device based on gradient diffusion film technology was used to prepare an adsorption film using agarose film as the basis, combining graphitized carbon black particles, MCX resin particles and HLB resin particles, and elution was determined by high-performance liquid chromatography-secondary mass spectrometry combined method. The concentration of antiviral drugs in the liquid can achieve the determination of the time average concentration.

Benefits of technology

It greatly reduces the labor intensity of sampling work and provides more environmentally meaningful time average concentration data. The adsorption film has high adsorption capacity and stable elution efficiency, which can effectively measure the concentration of various antiviral drugs in the water.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116251571B_ABST
    Figure CN116251571B_ABST
Patent Text Reader

Abstract

The invention discloses a method and device for determining antiviral drugs. The device is a DGT device, which comprises an adsorption membrane, a diffusion membrane and a filter membrane stacked in sequence; the adsorption membrane takes an agarose membrane as a matrix, and adsorption materials are distributed in the agarose membrane, and the particle size of the adsorption materials does not exceed 60 μm; the adsorption materials comprise any one or two of graphitized carbon black particles, MCX resin particles and HLB resin particles.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a detection method and a device, in particular to a determination method and a device for antiviral drugs. Background Art

[0002] Antiviral drugs are a type of prescription drug used to prevent and treat diseases caused by various viral infections. Their mechanism of action is to inhibit the synthesis of enzymes required by viruses at different life stages, thereby preventing viral replication and shortening the duration of the disease. With the development of society, the growth of demand for drugs, and the advancement of medical technology, the production and use of antiviral drugs are also increasing year by year. More and more drugs with antiviral potential are used in clinical treatment. Studies have shown that antiviral drugs are already widely present in sewage, surface water, groundwater and even drinking water. Although the concentration of antiviral drugs in the environment is low, antiviral drugs that enter the water body will still have toxic effects on aquatic organisms and may lead to biological resistance. For the human body, long-term and small-scale exposure to antiviral drugs may weaken the human immune system and produce the "three-cause" effects of carcinogenicity, teratogenicity and mutagenicity. With the increasing demand for disease treatment, the types and quantity of antiviral drugs will inevitably continue to grow. Since they are easy to remain in the environment for a long time and can have adverse environmental impacts at low concentrations, accurate and precise monitoring technologies and methods are essential for the analysis, research and early warning of antiviral drugs in water environment and soil. Reliable and stable sampling and measurement technologies are not only helpful in assessing the environmental risks of antiviral drugs, but also essential for understanding their environmental behavior.

[0003] At present, the detection method for antiviral drugs in the environment is mainly to collect environmental samples and transport them back to the laboratory through active sampling methods (grab water sampling method), and then prepare them into a state that can be measured on the machine through pretreatment techniques such as filtration, extraction, concentration, and constant volume. However, due to the low concentration of antiviral drugs in the environment, if a sufficiently stable method quantitative limit is to be obtained, a large number of water samples must be taken, and all samples need to be refrigerated. The water samples need to go through filtration, SPE column enrichment, elution, concentration, constant volume and other processing processes. These processes are not only very cumbersome, but also easy to introduce errors. Moreover, active sampling technology can only obtain the instantaneous concentration of the target drug in the water body at a certain point in time. Since the concentration of pollutants in the water body may fluctuate at different times, the instantaneous concentration cannot reflect the actual pollution status of the target pollutant. If the actual level of pollutants is to be reflected by active sampling technology, multiple sampling is required, which will increase the workload exponentially.

[0004] The biggest advantage of passive sampling techniques over active sampling techniques is that they can measure the time-averaged concentration of pollutants in water bodies, better capture the concentration fluctuations of pollutants in water, and are simple to operate, time-saving and labor-saving. There is no need for cumbersome sample pretreatment steps before measurement, and the introduction of errors is small. Diffusive gradients in thin films (DGT) is a passive sampling technology based on Fick's first diffusion law invented by David Williams and Zhang Hao at Lancaster University in the UK in the 1990s. Since its invention, it has been widely used in the determination of effective metal ions in water bodies, soils and sediments. It can measure the time-averaged concentration of pollutants in water bodies and the biologically effective concentration of pollutants in soil. There have been some reports on the use of DGT technology to determine various pharmaceutical compounds in the environment, but there have been no reports on the development of DGT methods for antiviral drugs. Summary of the invention

[0005] 1. Problem to be solved

[0006] In view of the problems that the existing sampling technology for antiviral drugs is time-consuming, complicated to operate, and can only obtain instantaneous concentrations when sampling and testing, the present invention provides a method and device for determining antiviral drugs, which aims to use a DGT device based on gradient diffusion film technology to determine antiviral drugs in water bodies, and to select suitable adsorption materials to make an adsorption membrane with high adsorption capacity and stable elution efficiency for antiviral drugs, and obtain the diffusion coefficient of antiviral drugs in the diffusion membrane. The present invention is used to determine antiviral drugs in water bodies. .

[0007] 2. Technical solution

[0008] Based on the above, the present invention provides the following technical solutions:

[0009] [1] In a first aspect of the present invention, there is provided an adsorption film for antiviral drugs, wherein the adsorption film is based on an agarose film, an adsorption material is distributed in the agarose film, and the particle size of the adsorption material does not exceed 60 μm;

[0010] in,

[0011] The adsorption material includes any one or two of graphitized carbon black particles (hereinafter abbreviated as ENVI-CARB), MCX resin particles (hereinafter abbreviated as MCX) and HLB resin particles (hereinafter abbreviated as HLB);

[0012] The adsorption film has a bending angle of not less than 60° when bent in at least one direction, and preferably has a bending angle close to 90°.

[0013] [1.1] An adsorption film for antiviral drugs according to any embodiment of the first aspect of the present invention, wherein the adsorption film is based on an agarose film, graphitized carbon black particles are distributed in the agarose film, and the particle size of the particles does not exceed 60 μm; or

[0014] The adsorption membrane is based on an agarose membrane, in which MCX resin particles and HLB resin particles are distributed, and the particle size of the particles does not exceed 60 μm; wherein the dosage (mass) ratio of the MCX resin particles to the HLB resin particles is (2-4): (0.5-1.5), and the preferred mass ratio is 3:1.

[0015] [1.2] An adsorption film for antiviral drugs according to any embodiment of the first aspect of the present invention, wherein the adsorption film is formed by solidifying an agar solution;

[0016] The agar solution is prepared by mixing agar powder, adsorption material and pure water in a mass ratio of 1:(7-13):50 and heating to boiling.

[0017] [1.3] According to any embodiment of the first aspect of the present invention, the adsorption film for antiviral drugs needs to be treated as follows before use:

[0018] Methanol cleaning, using methanol to soak and clean the adsorbent material; wherein the volume mass ratio of methanol to adsorbent material is (8-10): 5mL / g;

[0019] Ultrapure water cleaning: The adsorption material is cleaned with ultrapure water.

[0020] [1.4] According to any embodiment of the first aspect of the present invention, the adsorption film for antiviral drugs has a viscosity of not less than 73.41 μg / cm 2 adsorption capacity.

[0021] [2] A second aspect of the present invention provides an antiviral drug assay device,

[0022] The device is a DGT device;

[0023] The DGT device comprises an adsorption membrane, a diffusion membrane, and a filter membrane stacked in sequence;

[0024] The adsorption film is selected from the adsorption film according to any one of claims 1 to 3.

[0025] [2.1] According to the device for measuring antiviral drugs in any embodiment of the second aspect of the present invention, the diffusion membrane is an agarose membrane;

[0026] The filter membrane is a track-etched membrane.

[0027] [3] In a third aspect, the present invention provides a method for determining an antiviral drug.

[0028] (1) Place the DGT device into the water to be tested to adsorb antiviral drugs;

[0029] (2) taking the DGT device out of the water body to be tested, taking out the adsorption membrane, and eluting it with an eluent to obtain an eluate;

[0030] (3) The concentration of antiviral drugs in the eluate was determined by high performance liquid chromatography-tandem mass spectrometry.

[0031] [3.1] According to the method for determining antiviral drugs according to any embodiment of the third aspect of the present invention, the eluent is a mixed solution containing formic acid and acetonitrile; or,

[0032] The eluent is a mixed solution containing ammonia water and acetonitrile.

[0033] [3.2] According to the method for determining antiviral drugs of any embodiment of the third aspect of the present invention, the mixed solution containing formic acid and acetonitrile is specifically a mixed solution of formic acid aqueous solution and chromatographically pure acetonitrile, the ratio of the two is 4:6, and the concentration of the formic acid aqueous solution is 0.2% (V / V).

[0034] [3.3] According to the method for determining antiviral drugs of any embodiment of the third aspect of the present invention, the mixed solution containing ammonia water and acetonitrile is specifically a mixed solution of ammonia water and chromatographically pure acetonitrile, wherein the concentration of the ammonia water is 20% (V / V).

[0035] [3.2] According to the method for determining antiviral drugs according to any embodiment of the third aspect of the present invention,

[0036] The concentration of the antiviral drug in the water to be tested is between 0.01 and 500 mg / L.

[0037] Beneficial Effects

[0038] (1) The device based on gradient diffusion thin film (DGT) technology provided by the present invention uses ENVI-CARB particles, MCX resin particles and HLB resin particles as adsorption materials to prepare the adsorption membrane, which can effectively measure various antiviral drugs in water;

[0039] (2) The present invention provides a method for determining antiviral drugs in water bodies, which uses a DGT device for sampling. Compared with the existing active sampling method, it can greatly reduce the labor intensity of sampling work and provide a more environmentally meaningful time-averaged concentration.

[0040] (3) The present invention provides a method for determining antiviral drugs in water. The ENVI-CARB and MCX+HLB adsorption membranes can correspond to different antiviral drugs, respectively, have strong adsorption ability, and have a large adsorption capacity. According to the inventor's test, the adsorption capacity of these two adsorption membranes is 232.9 μg / piece and 230.5 μg / piece, respectively. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 This is a schematic diagram of the structure of the DGT device used in the embodiment of the present invention;

[0042] Figure 2 To use the DGT device in the embodiment of the present invention, the relationship between the mass of antiviral drugs adsorbed by MCX+HLB-DGT and the placement time (the solid line is the theoretical line), and the relationship between the mass of antiviral drugs adsorbed by ENVI-CARB-DGT and the placement time (the solid line is the theoretical line);

[0043] Figure 3 This is a diagram showing the adsorption effect of antiviral drugs at different pH values ​​using the DGT device in an embodiment of the present invention;

[0044] Figure 4 This is a diagram showing the adsorption effect of antiviral drugs at different pH values ​​using the DGT device in an embodiment of the present invention;

[0045] Figure 5 This is a diagram showing the adsorption effect of antiviral drugs at different ion concentrations using the DGT device in an embodiment of the present invention;

[0046] Figure 6 Adsorption ratio of antiviral drugs by MCX, MCX+HLB, ENVI-CARB, HLB and WCX adsorption membranes in Comparative Example 1;

[0047] Figure 7 The adsorption ratio of antiviral drugs on the DGT device, two different diffusion gels, and three different filter membranes in Comparative Example 2;

[0048] Figure 8 is the bending angle of MCX+HLB adsorption film

[0049] In the figure: 1, base; 2, adsorption membrane; 3, diffusion membrane; 4, filter membrane; 5, lid with sampling window; α, bending angle. DETAILED DESCRIPTION

[0050] The present disclosure may be more easily understood by reference to the following description in conjunction with the accompanying drawings and examples, all of which constitute a part of the present disclosure. It should be understood that the present disclosure is not limited to the specific products, methods, conditions or parameters described and / or shown herein. Further, the terms used herein are only used for the purpose of describing specific embodiments by way of example and are not intended to be limiting unless otherwise stated.

[0051] It should also be understood that, for the sake of clarity, certain features of the present disclosure may be described herein in the context of separate embodiments, but may also be provided in combination with each other in a single embodiment. That is, unless clearly incompatible or specifically not included, each separate embodiment is considered to be combinable with any other embodiment, and the combination is considered to represent another different embodiment. Conversely, for the sake of simplicity, the various features of the present disclosure described in the context of a single embodiment may also be provided individually or in any sub-combination. Finally, although a particular embodiment may be described as part of a series of steps or part of a more general structure, each step or substructure itself may also be considered to be an independent embodiment.

[0052] Unless otherwise indicated, it should be understood that each individual element in a list and each combination of individual elements in the list will be interpreted as a different embodiment. For example, a list of embodiments represented as "A, B, or C" should be interpreted to include embodiments "A", "B", "C", "A or B", "A or C", "B or C", or "A, B, or C".

[0053] In the present disclosure, the singular forms of the articles "a," "an," and "the" also include the corresponding plural references, and a reference to a specific value includes at least that specific value unless the context clearly indicates otherwise. Thus, for example, a reference to "a substance" is a reference to at least one of that substance and equivalents thereof.

[0054] The terms including ordinal numbers such as "first" and "second" can be used to explain various components or fluids, but these components and fluids are not limited by these terms. Therefore, without departing from the teachings of the present disclosure, these terms are only used to distinguish the component / fluid from another component / fluid.

[0055] When items are described by using the conjunction terms "... and / or...," etc., the description should be understood to include any one of the associated listed items and all combinations of one or more thereof.

[0056] In general, the use of the term "about" indicates an approximate value that may vary depending on the desired properties obtained by the disclosed subject matter, and will be interpreted in a context-dependent manner based on function. Therefore, one of ordinary skill in the art will be able to interpret a certain degree of difference on a case-by-case basis. In some cases, the number of significant figures used when expressing a particular value can be a representative technique for determining the difference allowed by the term "about". In other cases, a gradient in a range of values ​​can be used to determine the range of differences allowed by the term "about". Further, all ranges in this disclosure are inclusive and combinable, and reference to the values ​​stated in the range includes each value within the range.

[0057] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs; the terms used herein and / or include any and all combinations of one or more of the associated listed items.

[0058] As stated here:

[0059] MCX: refers to mixed cation exchange resin;

[0060] MCX+HLB; refers to mixed cation exchange-hydrophilic lipophilic balance mixed resin;

[0061] ENVI-CARB; refers to graphitized carbon black;

[0062] HLB; refers to hydrophilic lipophilic balance resin;

[0063] WCX: refers to weak cation exchange resin.

[0064] The present invention is further described below in conjunction with specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. The essential characteristics and remarkable effects of the present invention can be reflected from the following examples, and the described embodiments are part of the embodiments of the present invention, rather than all the embodiments, and therefore, they do not limit the present invention in any way, and those skilled in the art make some non-essential improvements and adjustments based on the content of the present invention, which all belong to the protection scope of the present invention.

[0065] The DGT device used in the following specific embodiments is as follows:

[0066] like Figure 1 As shown, the DGT device is assembled in sequence by a base 1, an adsorption membrane 2, a diffusion membrane 3, a filter membrane 4, and a cover with a sampling window 5. The base and the cover of the DGT device are made of acrylonitrile-butadiene-styrene copolymer.

[0067] As the "adsorption membrane 2", an agarose membrane is used as a matrix, and an adsorption material is distributed in the agarose membrane, and the particle size of the adsorption material does not exceed 60 μm; wherein the adsorption material includes any one or two of graphitized carbon black particles, MCX resin particles and HLB resin particles.

[0068] For example, a specific form of adsorption membrane is based on an agarose membrane, in which graphitized carbon black particles are distributed, and the particle size of the particles does not exceed 60 μm;

[0069] Another specific form of adsorption membrane is based on an agarose membrane, in which MCX resin particles and HLB resin particles are distributed, wherein the mass ratio of MCX to HLB is 3:1; and the particle size of the particles does not exceed 60 μm. It should be particularly noted that this form of adsorption membrane has a bending angle of not less than 60° when bent in at least one direction, and preferably has a bending angle close to 90°.

[0070] The “adsorption film 2” can be prepared in the following manner:

[0071] (1) Soak ENVI-CARB, MCX and HLB in methanol, and wash them with ultrapure water for later use. The specific steps are as follows:

[0072] Methanol washing: ENVI-CARB, MCX, and HLB were added to methanol solvent respectively, shaken and ultrasonicated until completely soaked, soaked, centrifuged, and the supernatant was removed to obtain a precipitated solid; the volume mass ratio of the methanol solvent to ENVI-CARB, MCX or HLB was 8:5 mL / g;

[0073] Ultrapure water cleaning: Add pure water to the deposited solid and shake it, centrifuge it, remove the supernatant, and repeat three times;

[0074] (2) Mix agar powder, prepared ENVI-CARB and MCX+HLB with pure water in a certain mass ratio, shake well and heat to boiling to form a uniform suspension;

[0075] (3) The prepared agar suspension is injected into the gap between two glass plates sandwiching a U-shaped Teflon sheet, the bubbles between the glass plates are squeezed out, the glass plates are placed horizontally and cooled at room temperature for 50 to 80 minutes, and the solution in the glass plates solidifies to form an adsorption film.

[0076] As the "diffusion membrane 3", an agarose membrane is selected;

[0077] As the "filter membrane 4", a track-etched membrane is selected;

[0078] The following are the steps for the determination of antiviral drugs using the DGT device described above:

[0079] (1) Assembly of the DGT device: The adsorption membrane, diffusion membrane and filter membrane are sequentially stacked between the base of the DGT device and the lid with a window to assemble the DGT device;

[0080] (2) Placing the DGT device: placing the DGT device in step (1) into the water to be tested to adsorb the antiviral drug;

[0081] (3) Recovery and elution of adsorption film: After taking the DGT device out of the water body to be tested, rinse the device with pure water, take out the adsorption film and place it in a glass bottle, and add the eluent to obtain the eluate;

[0082] (4) Determination of antiviral drugs: Determine the concentration of antiviral drugs in the eluate obtained in step (3) by high performance liquid chromatography-tandem mass spectrometry;

[0083] (5) Calculation of the adsorption amount of antiviral drugs: The adsorption amount of antiviral drugs on the adsorption film was calculated according to the following formula (I):

[0084] M=C e (V g +V e ) / f e (I)

[0085] Where, M is the amount of antiviral drugs adsorbed on the adsorption membrane, in ng; C e is the concentration of antiviral drugs in the eluate, in ng / mL; V g is the volume of the adsorption film, in mL; V e is the volume of the eluent in mL; f e is the elution efficiency of antiviral drugs, which is obtained by eluting adsorption membranes with known amounts of antiviral drugs adsorbed;

[0086] According to Fick's first diffusion law, the concentration of DGT is converted using the following formula (II) to calculate the concentration of antiviral drugs in water:

[0087] C DGT =M*Δ g / (D*A*t)(II)

[0088] In the formula, C DGT is the concentration of antiviral drugs in water, in ng / mL; Δ g is the sum of the thickness of the diffusion membrane and the filter membrane, in cm; D is the diffusion coefficient of the antiviral drug in the impurity filter membrane and the diffusion membrane, in cm 2 / s; A is the window area of ​​the DGT device, unit: cm 2 ; t is the placement time of the DGT device, in seconds.

[0089] As the "desorbent", a specific form thereof is a mixture of 0.2% (volume ratio) formic acid aqueous solution and chromatographically pure acetonitrile, wherein the ratio of formic acid aqueous solution to chromatographically pure acetonitrile is 4:6; if the adsorption membrane is an ENVI-CARB adsorption membrane, it is recommended to select this desorbent;

[0090] Another specific form of the "desorbent" is a 20% (volume ratio) ammonia acetonitrile solution; if the adsorption membrane is an MCX-HLB adsorption membrane, it is recommended to select this desorbent.

[0091] The present invention is further described below in conjunction with specific embodiments.

[0092] Example 1

[0093] In the DGT device of this embodiment, the diffusion membrane 3 selected is an agarose membrane;

[0094] Filter membrane 4 is a track-etched membrane (hydrophilic, diameter 25 mm, pore size 0.45 μm, Whatman);

[0095] There are two types of adsorption membrane 2:

[0096] The first method uses ENVI-CARB adsorption membrane; the particle size of ENVI-CARB used is 60 μm, and the agar solution is prepared in a ratio of 1:8:50 of agar powder, adsorption material (wet weight) and pure water. The prepared agar solution is injected into the gap between two glass plates sandwiched by a U-shaped Teflon sheet, and the bubbles between the glass plates are squeezed out. The glass plates are placed horizontally and cooled at room temperature for 80 minutes, and the solution in the glass plates solidifies to form an adsorption membrane.

[0097] When using this adsorption membrane, the subsequent eluent composition is as follows: 0.2% formic acid water-acetonitrile solution 4:6.

[0098] The second method uses MCX+HLB adsorption membrane; wherein the mass ratio of MCX to HLB is 4:6; the particle size of the MCX+HLB used is 60 μm, and during its preparation, an agar solution is prepared with an addition mass ratio of agar powder, adsorption material (wet weight) and pure water of 1:7:50. The prepared agar solution is injected into the gap between two glass plates sandwiched by a U-shaped Teflon sheet, and the bubbles between the glass plates are squeezed out. The glass plates are placed horizontally and cooled at room temperature for 60 minutes, and the solution in the glass plates solidifies to form an adsorption membrane.

[0099] When using this adsorption membrane, the subsequent eluent composition is as follows: 20% ammonia acetonitrile solution.

[0100] The specific steps for activating ENVI-CARB or MCX+HLB resin with methanol are as follows:

[0101] 1) Methanol activation: Add 50 g of ENVI-CARB, MCX or HLB resin to 70 mL of methanol solvent, soak for 30 min, then centrifuge at 7200 r / min for 5 min, remove the supernatant, and obtain a precipitated solid;

[0102] 2) Ultrapure water washing: pure water is added to the deposited solid for shaking treatment, centrifuged at a speed of 7200 r / min for 5 min, the supernatant is removed, and ultrapure water is washed three times to obtain activated ENVI-CARB, MCX or HLB resin;

[0103] 3) Storage: Add ultrapure water to the activated resin again in an amount that the liquid level exceeds the resin and then store it. When taking it out, pour out the upper clear liquid and directly weigh the remaining sediment (i.e., the activated resin), which is now in a wet weight state.

[0104] The specific detection steps are as follows:

[0105] (1) Placement of the DGT device: Place the DGT device in fully stirred water containing the antiviral drug to be tested for 3 to 168 hours, wherein the concentration of the antiviral drug in the water to be tested is 20 μg / L.

[0106] (2) Recovery and elution of resin adsorption film: After removing the DGT device from the water body to be tested, rinse the dirt on the surface of the device with pure water, then take out the ENVI-CARB or MCX+HLB resin adsorption film, place it in a glass bottle, add eluent (the eluent for ENVI-CARB adsorption film is 0.2% formic acid water-acetonitrile solution 4:6, and the eluent for MCX-HLB adsorption film is 20% ammonia acetonitrile solution) and then ultrasonicate for 30 minutes to obtain the eluate.

[0107] (3) Determination of antiviral drugs: The concentration of antiviral drugs in the eluate obtained in step (3) is determined by high performance liquid chromatography-tandem mass spectrometry.

[0108] (4) Calculation of the adsorption amount of antiviral drugs: The adsorption amount of antiviral drugs on the resin adsorption film was calculated according to the following formula (I):

[0109] M=C e (V g +V e ) / f e (I)

[0110] Where, M is the adsorption amount of antiviral drugs on the resin adsorption membrane, unit is ng; C e is the concentration of antiviral drugs in the eluate, in ng / mL; V g is the volume of the resin adsorption film, in mL; V e is the volume of the eluent in mL; f e It is the elution efficiency of antiviral drugs, which is obtained by eluting the resin adsorption membrane with a known amount of antiviral drugs adsorbed;

[0111] According to Fick's first diffusion law, the concentration of DGT is converted using the following formula (II) to calculate the concentration of antiviral substances in water:

[0112] C DGT =M*Δ g / (D*A*t)(II)

[0113] In the formula, C DGT is the concentration of antiviral drugs in water, in ng / mL; Δ g is the sum of the thickness of the diffusion membrane and the filter membrane, in cm; D is the diffusion coefficient of the antiviral drug in the diffusion membrane, in cm 2 / s; A is the window area of ​​the DGT device, unit: cm 2 ; t is the placement time of the DGT device, in seconds.

[0114] In this embodiment, when the measuring temperature is 25° C., the diffusion coefficients of the various antiviral substances measured above are shown in Table 1.

[0115] Table 1. Diffusion coefficients of various antiviral drugs

[0116]

[0117] Window area A: 3.14cm 2 ;

[0118] The above antiviral drugs were tested within a test time t of 3 to 168 hours.

[0119] The concentrations of the various antiviral drugs measured above (C DGT ) to the actual concentration (20 μg / L) were all within the range of 0.9 to 1.1, meeting the requirements for DGT determination. Figure 2 As shown in the figure, the mass of antiviral drugs enriched on the DGT adsorption film is consistent with the mass calculated by the DGT theoretical formula, indicating that DGT can well determine the concentration of antiviral drugs in water when placed for a long time.

[0120] Example 2

[0121] In this embodiment, the DGT technology is used to determine the effect of antiviral drugs in water at different pH values, wherein the concentration of the antiviral drugs in the water to be tested is 20 μg / L, and the pH values ​​of the aqueous solutions to be tested are 3.16, 5.57, 7.23, 8.41 and 9.74, respectively.

[0122] like Figure 3 , 4 As shown, for DGT with ENVI-CARB as adsorption membrane, the concentration of most antiviral drugs C calculated according to the formula DGT Compared with the actual measurement of antiviral drug C in solution solu The ratio of MCX+HLB to DGT is between 0.9 and 1.1, indicating that the pH of the water body has no significant effect on the determination of most DGTs. However, for SOF, SOP, 3TC and OTV, this adsorption film is not suitable as an adsorption film. The DGT with MCX+HLB as the adsorption film has a C value of SOF, SOP, 3TC and OTV. DGT The actual concentration C in the measured solution solu The ratio is between 0.9 and 1.1, indicating that the MCX+HLB adsorption membrane can make up for the shortcomings of the ENVI-CARB adsorption membrane.

[0123] Example 3

[0124] In this embodiment, the influence of antiviral drugs in water is determined by DGT technology under different ion concentrations. In this embodiment, a DGT device is used to determine the antiviral drugs in water. The DGT device is placed in fully stirred water containing the antiviral drugs to be tested for 24 hours. The concentration of the antiviral drugs in the water to be tested is 20 μg / L, and the ion concentrations of the aqueous solutions to be tested (in terms of NaCl) are: 0.1, 1, 10, 100, and 500 mmol / L, respectively.

[0125] like Figure 5 As shown, for DGT with ENVI-CARB as the adsorption membrane, the antiviral drug concentration C calculated according to the formula DGT The concentration of antiviral drugs in the actual measured solution C solu The ratios are mostly between 0.9 and 1.1, indicating that the ionic strength of the water for these substances has no significant effect on the determination of DGT. However, RBV, FTC and 3TC cannot be used in water with an ionic strength exceeding 100mmol / L, and ENVI-CARB is not applicable to SOP. DGT with MCX+HLB as the adsorption membrane can make up for the shortcomings of ENVI-CARB in determining SOP. However, for FTC and 3TC, the ionic strength still cannot exceed 100mmol / L.

[0126] Comparative Example 1

[0127] The purpose of this comparative example is to compare the adsorption capacity of several adsorption membranes for antiviral drugs. The adsorption membranes are:

[0128] MCX adsorption membrane, MCX+HLB adsorption membrane, ENVI-CARB adsorption membrane, HLB adsorption membrane, WCX adsorption membrane.

[0129] The above-mentioned adsorption membranes were placed in a solution containing 20 ng / mL of antiviral drugs and shaken for 24 hours. The membranes were taken out and eluted to obtain the antiviral drugs in the eluate.

[0130] Depend on Figure 6 It can be seen that the MCX adsorption membrane, MCX+HLB adsorption membrane and ENVI-CARB adsorption membrane have strong adsorption capacity for most antiviral drugs. However, due to the high brittleness of the MCX adsorption membrane, it is easy to break when placed in water for a long time, while the adsorption effect of the MCX+HLB adsorption membrane is consistent with that of the MCX adsorption membrane, but its flexibility far exceeds that of the MCX adsorption membrane, making it more suitable for field deployment. The first type: using agarose membrane as the matrix, with activated XAD18 resin distributed in the agarose membrane.

[0131] Further tests have shown that the bending angle of the MCX adsorption film can reach up to 60°. If the bending angle continues to increase, it will break. However, the bending angle of the MCX+HLB adsorption film can reach 80° without breaking. The bending angle is as follows: Figure 8 shown.

[0132] Comparative Example 2

[0133] First of all, it should be pointed out that filter membranes and diffusion membranes are also important components of the DGT device. When using DGT technology to determine antiviral drugs in water, it is necessary not only to select a suitable adsorption membrane, but also a suitable filter membrane. The amount of adsorption of the target by the filter membrane must be as small as possible so as not to affect the diffusion of the target to the resin adsorption membrane. Different organic substances have different adsorption capacities on different filter membranes. Therefore, before method development, a suitable filter membrane must be selected for the target substance to reduce its adsorption or retention of the detection target, resulting in measurement errors.

[0134] This comparative example selects three filter membranes and two diffusion membranes to test the adsorption performance of antiviral drugs on the filter membranes and diffusion membranes. The specific steps are as follows:

[0135] (1) Select three filter membranes, such as Figure 7, Nuclepore track-etched membrane (PC), polyethersulfone membrane (PES) and polytetrafluoroethylene membrane (PTFE), the new membrane was soaked in ultrapure water containing 0.01M NaCl for one day. Two diffusion membranes were selected, agarose diffusion membrane (AGE) and acrylamide diffusion membrane (APA).

[0136] (2) The three filter membranes and two diffusion membranes were placed in 10 mL Erlenmeyer flasks containing 20 μg / L of the target antiviral drug and shaken at 25°C for 24 hours.

[0137] (3) Take 200 μ / L water sample from the flask before and after the membrane is placed, and measure the concentration of the target substance in the water sample.

[0138] (4) Calculate the adsorption percentage of the target substance by the membrane using the following formula:

[0139] Adsorption % = (C a -C b ) / Ca×100%

[0140] Among them C a is the original target concentration in the conical flask, C b is the concentration of the target substance in the conical flask after the membrane is taken out.

[0141] At the same time, as a component of DGT, the DGT shell is also tested synchronously.

[0142] like Figure 6 As shown, the inventors have concluded through professional theoretical analysis and repeated experiments that only PC membranes have the least adsorption of the target substance, and filter membranes made of polyethersulfone or polytetrafluoroethylene can adsorb a large amount of antiviral drugs, causing the substance to be unable to form a diffusion gradient in the filter membrane and the diffusion membrane and then be captured by the resin adsorption membrane. The agarose membrane adsorbs less antiviral drugs than the acrylamide membrane. In addition, the DGT shell adsorbs very little antiviral drugs. Therefore, when measuring antiviral drugs in water, PC membranes are selected as the filter membranes of the DGT device, and agarose membranes are selected as the diffusion membranes of the DGT device.

Claims

1. An adsorption film for antiviral drugs, It is characterized in that The adsorption membrane is based on an agarose membrane, in which MCX resin particles and HLB resin particles are distributed, and the particle size of the particles does not exceed 60 μm; The adsorption film is formed by solidification of agar solution; The agar solution is prepared by mixing agar powder, adsorption material and pure water in a mass ratio of 1: (7-13): 50 and heating to boiling; The adsorption film has a bending angle of not less than 60° when bent in at least one direction.

2. The adsorption film of antiviral drugs according to claim 1, It is characterized in that The adsorption material needs to be processed as follows before use: Methanol cleaning, using methanol to soak and clean the adsorbent material; wherein the volume mass ratio of methanol to adsorbent material is (8-10): 5 mL / g; Ultrapure water cleaning: The adsorption material is cleaned with ultrapure water.

3. The adsorption film of antiviral drugs according to any one of claims 1 to 2, It is characterized in that The adsorption film has a g / cm 2 adsorption capacity.

4. A device for measuring antiviral drugs, It is characterized in that The device is a DGT device; The DGT device comprises an adsorption membrane, a diffusion membrane, and a filter membrane stacked in sequence; The adsorption film is selected from the adsorption film according to any one of claims 1 to 3.

5. The antiviral drug assay device according to claim 4, It is characterized in that The diffusion membrane is an agarose membrane; The filter membrane is a track-etched membrane.

6. A method for determining antiviral drugs, It is characterized in that (1) Place the DGT device into the water to be tested to adsorb antiviral drugs; (2) Take out the DGT device from the water body to be tested, take out the adsorption membrane, and elute it with an eluent to obtain an eluate; (3) The concentration of antiviral drugs in the eluate was determined by high performance liquid chromatography-tandem mass spectrometry.

7. The method for determining the antiviral drug according to claim 6, It is characterized in that The eluent is a mixed solution containing formic acid and acetonitrile; or, The eluent is a mixed solution containing ammonia water and acetonitrile.

8. The method for determining the antiviral drug according to claim 7, It is characterized in that The concentration of the antiviral drug in the water to be tested is between 0.01 and 500 mg / L.

Citation Information

Patent Citations

  • Method for measuring psychotropic and anaesthetic drugs

    CN110108809A

  • Gel adsorption film, gradient diffusion device and application in artificial sweetener sampling

    CN115254063A

  • In-situ detection method for polycyclic aromatic hydrocarbon in organic contaminated site soil

    CN115753320A